A Corporate Commitment to Partnership Success
Repligen's business has been built on the success of its valued partnerships and collaborations with life sciences and biopharmaceutical companies worldwide. Repligen has a earned a reputation as a reliable technology "partner of choice" and has a strong commitment to growth through mutually beneficial agreements. The Company is currently exploring opportunities to expand and diversify its core bioprocessing business, while seeking development partners for its clinical portfolio of drug candidates.
Repligen BioProcessing Partnering Opportunities
Repligen has built a highly specialized biotechnology and life sciences research and development (R&D) group, a set of flexible business practices and commercialization channels that can support direct to end user customer sales or OEM supply. We are routinely engaged in partnerships that leverage all our expertise from contract or co-development programs in the many bioprocessing disciplines including protein-based R&D, fermentation, purification, analytical tools development and commercialization.
Repligen BioProcessing is continuously looking for new partnership opportunities where we can leverage:
- Our manufacturing and R&D expertise as an OEM development and manufacturing partner
- Our commercial and financial strengths to create commercial alliances through acquisition, license or co-marketing agreements
Please visit the Repligen BioProcessing website.
Do you have an idea, proposal or just a question for BioProcessing Partnering? If so, please contact please contact us.
Repligen Therapeutic Partnering Opportunities
Repligen is actively seeking partners for the further development of the novel drug candidates in its therapeutic pipeline. Our partnering portfolio includes small molecule and biologic compounds at various stages of clinical development, addressing diseases in the areas of neurology and gastroenterology.
RG1068 (synthetic human secretin) to improve pancreatic imaging:
- Orphan Drug and Fast Track designated biologic
- A Phase 3 study has been completed for the improved detection of pancreatic duct abnormalities, in combination with MRI, in patients with pancreatitis; primary endpoints were met with statistical significance and RG1068 shown to be safe and well-tolerated in 258 patients evaluated
- Additional Phase 3 clinical data required by U.S. FDA to support approval of New Drug Application
RG2833 for the potential treatment of Friedreich's Ataxia (FA):
- Orphan drug designated small molecule HDAC inhibitor
- In Phase 1 development for the treatment of FA, a inherited neurodegenerative disease caused by a single gene defect that results in inadequate production of the key protein frataxin
- FA presents in childhood and leads to progressive loss of muscle and nerve function, often resulting in loss of life by early adulthood
- Preclinical studies showed RG2833 increases production of frataxin in patients cells; Phase 1 patient study outcomes are expected during the first half of 2013
To learn more about Repligen's partnering opportunities, please contact us.